EPS for HTG Molecular Diagnostics, Inc. (HTGM) Expected At $-0.23

March 21, 2018 - By Rodney Autry

 EPS for HTG Molecular Diagnostics, Inc. (HTGM) Expected At $ 0.23

Analysts expect HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) to report $-0.23 EPS on March, 22 after the close.They anticipate $0.53 EPS change or 69.74 % from last quarter’s $-0.76 EPS. After having $-0.46 EPS previously, HTG Molecular Diagnostics, Inc.’s analysts see -50.00 % EPS growth. The stock decreased 3.24% or $0.18 during the last trading session, reaching $5.38. About 2.33 million shares traded or 14.50% up from the average. HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has risen 34.13% since March 21, 2017 and is uptrending. It has outperformed by 17.43% the S&P500.

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Ratings Coverage

Among 3 analysts covering HTG Molecular Diagnostics (NASDAQ:HTGM), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. HTG Molecular Diagnostics has $12.0 highest and $5.0 lowest target. $5.33’s average target is -0.93% below currents $5.38 stock price. HTG Molecular Diagnostics had 14 analyst reports since August 24, 2015 according to SRatingsIntel. Canaccord Genuity maintained the stock with “Buy” rating in Monday, January 8 report. The stock of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has “Buy” rating given on Wednesday, January 24 by H.C. Wainwright. H.C. Wainwright maintained HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) rating on Tuesday, September 12. H.C. Wainwright has “Buy” rating and $6.0 target. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, August 9. The rating was maintained by Canaccord Genuity with “Buy” on Monday, August 24. The rating was initiated by Rodman & Renshaw on Monday, August 22 with “Buy”. The firm has “Buy” rating by H.C. Wainwright given on Thursday, February 1. Canaccord Genuity maintained HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) on Friday, January 5 with “Buy” rating. The firm earned “Buy” rating on Friday, July 28 by H.C. Wainwright. The stock has “Buy” rating by H.C. Wainwright on Wednesday, November 8.

HTG Molecular Diagnostics, Inc. develops and markets services and products based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company has market cap of $149.81 million. The company's products, HTG Edge and HTG EdgeSeq platforms include instrumentation , consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies. It currently has negative earnings. The Company’s platforms generate a molecular profiling library for detection using next-generation sequencing.

More recent HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) news were published by: Seekingalpha.com which released: “HTG Molecular Diagnostics’ (HTGM) CEO TJ Johnson on Q3 2017 Results – Earnings …” on November 08, 2017. Also Streetinsider.com published the news titled: “HTG Molecular Diagnostics (HTGM) Announces New Australian Patent” on February 26, 2018. Prnewswire.com‘s news article titled: “Pre-Market Technical Scan on Medical Research Equities — HTG Molecular …” with publication date: March 12, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.